

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

CT26.WT

RRID:CVCL_7256

Type: Cell Line

Proper Citation

RRID:CVCL_7256

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_7256

Proper Citation: RRID:CVCL_7256

Description: Cell line CT26.WT is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Female

Disease: Mouse colon adenocarcinoma

Defining Citation: [PMID:7722321](#), [PMID:11089883](#), [PMID:24621249](#), [PMID:25277546](#), [PMID:31220119](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: CT26.WT

Synonyms: CT-26 WT, CT26.wt, CT26WT

Cross References: BTO:BTO_0006018, CLO:CLO_0002631, ATCC:CRL-2638, BCRC:60447, BCRJ:0402, BioSample:SAMN11397649, CCRID:1101MOU-PUMC000275, CCRID:3101MOUTCM37, ChEMBL-Cells:ChEMBL4513106, ChEMBL-Targets:ChEMBL4513123, CLS:305178, KCB:KCB 201207YJ, PubChem_Cell_line:CVCL_7256, Ubigen:YC-B003, Wikidata:Q54814710

ID: CVCL_7256

Hierarchy: cvcl_7254

Record Creation Time: 20220427T215526+0000

Record Last Update: 20260815T232131+0000

Ratings and Alerts

No rating or validation information has been found for CT26.WT.

No alerts have been found for CT26.WT.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 192 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gruber DR, et al. (2026) Targeted Delivery of a Potent STING Agonist Payload via an Antibody-Drug Conjugate Drives Robust Antitumor Activity in Preclinical Models. *Molecular cancer therapeutics*, 25(3), 457.

Arnaut LG, et al. (2026) Flash Photodynamic Therapy - How the Saturation of Photosensitizer Absorption Enables Selective and Deeper Tumor Treatments. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(1), e13199.

Fu J, et al. (2026) mRNA lipid-nanoparticle-mediated mitochondrial apoptosis augments adoptive T cell immunotherapy. *Cell reports. Medicine*, 7(4), 102706.

Zhang Y, et al. (2026) Synergistic photodynamic therapy and IDO inhibition via a self-assembled nanomedicine potentiates PD-L1 blockade in gastrointestinal cancers. *Biomaterials advances*, 185, 214849.

Deng Y, et al. (2026) Dual-system engineered bacteria and dendritic cells enable precise intratumoral IL-12 delivery and potent antitumor immunity. *Cell reports. Medicine*, 7(6), 102801.

Deck AJ, et al. (2026) IFN- γ PET imaging stratifies and predicts response to CD137 agonism in a syngeneic colorectal tumor model. *Journal for immunotherapy of cancer*, 14(6).

Sayin S, et al. (2026) Bacterial population dynamics during colonization of solid tumors. *Molecular systems biology*, 22(3), 412.

Zhang B, et al. (2026) Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine-Driven Immune Suppression in Colorectal Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(5), e13986.

Friedman DJ, et al. (2026) Fluorescence tracking Treg movement identifies anti-CCR8 and radiation as a therapeutic combination. *iScience*, 29(2), 114572.

Starenko D, et al. (2026) Lopinavir Derivative as Potent P-gp Inhibitor Enables Delivery through HPMA Copolymer Conjugates and Overcoming Tumor Chemoresistance to Conventional Cytostatic Drugs. *Biomacromolecules*, 27(2), 1510.

Huang F, et al. (2026) Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer. *iScience*, 29(6), 115849.

Zhang Y, et al. (2026) Targeting EP2/EP4-driven expansion of suppressive VSIG4^{high} macrophages overcomes immunotherapy resistance in colorectal cancer. *Cell reports*, 45(6), 117450.

Tan L, et al. (2026) S100A14 promotes colorectal cancer progression and anti-PD-1 resistance via UPF1-mediated activation of the non-canonical NF- κ B signaling. *Cell death & disease*, 17(1).

Feng Q, et al. (2026) Targeting severe acidity for tumor-activatable Interleukin-2 therapy. *Cell reports. Medicine*, 7(1), 102572.

He S, et al. (2026) 14,15-epoxyeicosatrienoic acid drives intestinal adenoma growth and its value as an early biomarker for intestinal adenoma occurrence. *Oncogenesis*, 15(1).

Liu J, et al. (2026) Targeting the noncanonical function of metabolic enzyme PHGDH in driving PD-L1 expression and cancer immune evasion. *Cell reports. Medicine*, 7(4), 102704.

Li X, et al. (2026) Engineering *Escherichia coli* Nissle 1917 to scavenge lactate enhances anti-tumor immunity. *Journal of controlled release : official journal of the Controlled Release Society*, 392, 114738.

Ou C, et al. (2026) A harmless-to-harmful switchable and spatiotemporally activated nano-CRISPR hierarchically amplifies ferroptosis in melanoma. *Cell reports. Medicine*, 7(4), 102718.

Liu A, et al. (2026) Soluble Uric Acid Drives CD8⁺ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation. *Cancer research*, 86(14), 3459.

Wang L, et al. (2026) Licoisoflavone A potentiates oxaliplatin efficacy in colorectal cancer by dual targeting arginine metabolism of tumor microenvironment and cancer cells. *Chinese medicine*, 21(1).